Jim Caggiano

Jim Caggiano is the CEO of Evolve Biologics, bringing nearly 30 years of experience in the biotechnology, pharmaceutical and medical device marketplaces. Previously, he was CEO of Dendreon Pharmaceuticals LLC. Among his earlier leadership roles in the biotech, pharmaceutical and medical device industries, Caggiano successfully directed the divestiture of Allergan’s Lap-Band to Apollo Endosurgery in 2013. In 2015, Caggiano was hired by Valeant Pharmaceuticals International to run Dendreon, where he doubled the company’s enterprise value. He then developed and implemented the strategy for the 2017 sale of Dendreon to Sanpower Group for $820M. Sanpower subsequently appointed him CEO, where he led the previously bankrupt enterprise to achieve over $100 million in EBITDA in 2018 and 2019. Earlier in his career, Caggiano held senior roles at Allergan, Inc., Abbott Laboratories and TAP Pharmaceuticals. Caggiano earned a bachelor’s degree in agricultural economics (business) from Cornell University on an Army ROTC scholarship then served four years as an Armour Officer in Germany. He also holds an MBA from the Kellogg School of Management at Northwestern University.